Modeling of cancer virotherapy with recombinant measles viruses

Journal of Theoretical Biology

Volumn 252, Issue 1, 2008, Pages 109-122

  Bajzer, Željko ^a   Carr, Thomas ^b   Josić, Krešimir ^c   Russell, Stephen J ^d   Dingli, David ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d University of Houston   (United States)

Author keywords

Cancer therapy; Oscillatory dynamical systems; Population dynamics; Tumor growth modeling

Indexed keywords

MEASLES VACCINE;

CANCER; MEASLES; POPULATION DYNAMICS; TUMOR; VACCINE;

ARTICLE; COMPUTER SIMULATION; ERADICATION THERAPY; EXPERIMENTAL STUDY; MEASLES VIRUS; NEOPLASM; OSCILLATION; PRIORITY JOURNAL; TUMOR GROWTH; VALIDATION STUDY; VIROTHERAPY; VIRUS RECOMBINANT;

ANIMALS; CELL DIVISION; HUMANS; MEASLES VIRUS; MICE; MICE, SCID; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGNOSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

MEASLES VIRUS;

EID: 41949097523     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2008.01.016     Document Type: Article

References (42)

1. Anderson B.D., Nakamura T., Russell S.J., and Peng K.W. High cd46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64 14 (2004) 4919-4926
2. Bajzer Z., Marušić M., and Vuk-Pavlović S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math. Comput. Modelling 23 (1996) 31-46
3. Bajzer Z., Vuk-Pavlović S., and Huzak M. Mathematical modeling of tumor growth kinetics. In: Adam J., and Bellomo N. (Eds). A Survey of Models for Tumor-immune System Dynamics (1997), Birkhäuser, New York, NY 89-133 (Chapter 3)
4. Bruaer F., and Castillo-Chavez C. Mathematical Models in Population Biology and Epidemiology (2000), Springer, New York, NY
5. Byrne H.M. Modelling avascular tumour growth. In: Preziosi L. (Ed). Cancer Modelling and Simulation (2003), CRC Press, Boca Raton, FL 75-120 (Chapter 4)
6. Cameron D.A., Ritchie A.A., and Miller W.R. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. Eur. J. Cancer 37 12 (2001) 1545-1553
7. Chignola R., Schenetti A., Andrighetto G., Chiesa E., Foroni R., Sartoris S., Tridente G., and Liberati D. Forecasting the growth of multicell tumour spheroids: implications for the dynamic growth of solid tumours. Cell Prolif. 33 4 (2000) 219-229
8. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., Morris J.C., and Russell S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103 5 (2004) 1641-1646
9. Dingli D., Cascino M.D., Josić K., Russell S.J., and Bajzer Z. Mathematical modeling of cancer radiovirotherapy. Math. Biosci. 199 1 (2006) 55-78
10. Dingli D., Kemp B.J., O'Connor M.K., Morris J.C., Russell S.J., and Lowe V.J. Combined I-124 positron emission tomography/computed tomography imaging of nis gene expression in animal models of stably transfected and intravenously transfected tumor. Mol. Imaging Biol. 8 1 (2006) 16-23 (1536-1632)
11. Ermantrout B. Simulating, Analyzing, and Animating Dynamical Systems: A Guide to Xppaut for Researchers and Students (2002), Society for Industrial and Applied Mathematics, Philadelphia, PA
12. Friedman A., Tian J., Fulci G., Chiocca E., and Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. 66 (2006) 2314-2319
13. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A., and Fielding A.K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97 12 (2001) 3746-3754
14. Hadac E.M., Peng K.W., Nakamura T., and Russell S.J. Reengineering paramyxovirus tropism. Virology 329 2 (2004) 217-225
15. Heaney J., Barrett T., and Cosby S.L. Inhibition of in vitro leukocyte proliferation by morbilliviruses. J. Virol. 76 7 (2002) 3579-3584
16. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7 7 (2001) 781-787
17. Marušić M., Bajzer Z., Vuk-Pavlović S., and Freyer J.P. Tumor growth in vivo and as multicellular spheroids compared by mathematical models. Bull. Math. Biol. 56 4 (1994) 617-631
18. McDonald C.J., Erlichman C., Ingle J.N., Rosales G.A., Allen C., Greiner S.M., Harvey M.E., Zollman P.J., Russell S.J., and Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 99 2 (2006) 177-184
19. Nakamura T., Peng K.W., Vongpunsawad S., Harvey M., Mizuguchi H., Hayakawa T., Cattaneo R., and Russell S.J. Antibody-targeted cell fusion. Nat. Biotechnol. 22 3 (2004) 331-336
20. Nakamura T., Peng K.W., Harvey M., Greiner S., Lorimer I.A., James C.D., and Russell S.J. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23 2 (2005) 209-214
21. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., Kuhn J., McCarty T., Landers S., Blackburn A., Romel L., Randlev B., Kaye S., and Kirn D. Phase ii trial of intratumoral administration of onyx-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19 2 (2001) 289-298
22. Offord, C., Bajzer, Ž., 2006. A hybrid global optimization algorithm involving simplex and inductive search. Lecture Notes in Computer Science, vol. 2074. Springer, Berlin, pp. 680-688.
23. Ong H.T., Timm M.M., Greipp P.R., Witzig T.E., Dispenzieri A., Russell S.J., and Peng K.W. Oncolytic measles virus targets high cd46 expression on multiple myeloma cells. Exp. Hematol. 34 6 (2006) 713-720
24. Pecora A.L., Rizvi N., Cohen G.I., Meropol N.J., Sterman D., Marshall J.L., Goldberg S., Gross P., O'Neil J.D., Groene W.S., Roberts M.S., Rabin H., Bamat M.K., and Lorence R.M. Phase i trial of intravenous administration of pv701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20 9 (2002) 2251-2266
25. Peng K.W., Ahmann G.J., Pham L., Greipp P.R., Cattaneo R., and Russell S.J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98 7 (2001) 2002-2007
26. Peng K.W., Facteau S., Wegman T., O'Kane D., and Russell S.J. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 8 5 (2002) 527-531
27. Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., and Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62 16 (2002) 4656-4662
28. Peng K.W., Hadac E.M., Anderson B.D., Myers R., Harvey M., Greiner S.M., Soeffker D., Federspiel M.J., and Russell S.J. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 13 8 (2006) 732-738
29. Phuong L.K., Allen C., Peng K.W., Giannini C., Greiner S., TenEyck C.J., Mishra P.K., Macura S.I., Russell S.J., and Galanis E.C. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63 10 (2003) 2462-2469
30. Reid T., Galanis E., Abbruzzese J., Sze D., Andrews J., Romel L., Hatfield M., Rubin J., and Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase i trial. Gene Ther. 8 21 (2001) 1618-1626
31. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., Randlev B., Heise C., Uprichard M., Hatfield M., Rome L., Rubin J., and Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase ii viral, immunologic, and clinical endpoints. Cancer Res. 62 21 (2002) 6070-6079
32. Russell S.J. RNA viruses as virotherapy agents. Cancer Gene Ther. 9 12 (2002) 961-966
33. Schneider U., von Messling V., Devaux P., and Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76 15 (2002) 7460-7467
34. Spratt J.A., von Fournier D., Spratt J.S., and Weber E.E. Decelerating growth and human breast cancer. Cancer 71 6 (1993) 2013-2019
35. Tao Y., and Guo Q. The competitive dynamics between tumor cells, a replication-competent virus and an immune response. J. Math. Biol. 51 1 (2005) 37-74
36. Wein L.M., Wu J.T., and Kirn D.H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 63 6 (2003) 1317-1324
37. Whistler T., Bellini W.J., and Rota P.A. Generation of defective interfering particles by two vaccine strains of measles virus. Virology 220 2 (1996) 480-484
38. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61 8 (2001) 3501-3507
39. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum. Gene Ther. 14 2 (2003) 153-159
40. Wodarz D., and Komarova N. Computational Biology of Cancer: Lecture Notes and Mathematical Modeling (2005), World Scientific Publishing Company, Hackensack, NJ
41. Wu J.T., Byrne H.M., Kirn D.H., and Wein L.M. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull. Math. Biol. 63 4 (2001) 731-768
42. Wu J.T., Kirn D.H., and Wein L.M. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull. Math. Biol. 66 4 (2004) 605-625